Photocure ASA
OSE:PHO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
48.05
70.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Photocure ASA
Photocure ASA
Cash from Investing Activities
Photocure ASA
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Cash from Investing Activities
-kr648k
|
CAGR 3-Years
84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Cash from Investing Activities
-kr41.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Cash from Investing Activities
-kr15.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-159%
|
CAGR 10-Years
-32%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Cash from Investing Activities
-kr14.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Cash from Investing Activities?
Cash from Investing Activities
-648k
NOK
Based on the financial report for Jun 30, 2024, Photocure ASA's Cash from Investing Activities amounts to -648k NOK.
What is Photocure ASA's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
84%
The average annual Cash from Investing Activities growth rates for Photocure ASA have been 84% over the past three years .
You don't have any saved screeners yet
